Picture loading failed.

Anti-CD74 therapeutic antibody (Pre-made Milatuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-344-1mg 1mg 3090
GMP-Bios-ab-344-10mg 10mg 21890
GMP-Bios-ab-344-100mg 100mg 148000
GMP-Bios-ab-344-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CD74 therapeutic antibody (Pre-made Milatuzumab biosimilar,Whole mAb)
INN Name Milatuzumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2007
Year Recommended2008
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedGraft-versus-host disease;Haematological malignancies;Chronic lymphocytic leukaemia;Multiple myeloma;Non-Hodgkin's lymphoma;Systemic lupus erythematosus
Development Techna